Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Click: http://www.melogia.com Sarantos Releases Newest Rap Hip Hop Music Video That Will Answer The Break-Up Question - “Why”
Sarantos helps every woman out there who has ever wondered what a man thinks about after a relationship ends and when an ex refuses to answer them.
For most of his life when Sarantos had to go through a breakup, he would always turn to his dad for advice. Sadly, not too long ago Sarantos lost his devoted father after a hard-fought battle to lung cancer. This experience had a major impact on Sarantos' life, enabling him to overcome any obstacle that may present itself. The Chicago singer has since been driven to remain strong and positive not just for himself but also for his friends & fans.
The promising artist quickly responded to his fans' request by releasing the music video to his rap hip hop song "Why." With this newly released video, Sarantos hopes to encourage everyone to mend their heart and use their new-found understanding to move forward with their lives.
“Going through life’s hardships has given me the willpower to write songs and to sing from the heart,” says Sarantos. “I wouldn’t have had the passion or energy to strive for my dreams if it wasn’t for my loving family and friends. I know my father would have been very proud of me!”
Sarantos just released his 7th music video for “Why.” The song was released on July 1st, 2014.
Sarantos describes it as, “a hip and powerful rap song that answers the basic questions on every woman's mind about their relationship. Why does he love me? Why does he put up with me? Why does he stay here? Does he care for me? Does he really love me? The answer is lengthy and before he met you, he couldn't tell anyone why but now he can. He tells her exactly why!”
Sarantos has a strong motivation with his musical passion to raise money for charity. One-third of any music-related sales profits are going straight to charity. For “Why,” Sarantos has chosen the Aesthetic Surgery Education and Research Foundation. His love for helping others to improve has always been his motivation, and now, his music can reflect that.
Sarantos Facebook artist page:
https://www.facebook.com/Sarantosmelogia
Sarantos Twitter:
http://www.twitter.com/sarantosmelogia
Sarantos Youtube:
http://www.youtube.com/user/SarantosMelogia
Sarantos iTunes:
http://bit.ly/SarantosAppleStore
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
‘Tackling hepatitis C: Moving towards an integrated policy approach’, a report published by The Economist Intelligence Unit (EIU) today reveals that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease. The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patients' lives and healthcare systems.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400562-janssen-new-reports-hepatitis-c
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Supergoop!® announces its partnership with entrepreneur and international tennis sensation Maria Sharapova, welcoming her to the Supergoop! team as a co-owner with Founder and CEO Holly Thaggard. Supergoop! is the first and only multi-functional skincare line in prestige distribution with a foundation in UV protection and 100% dedication to sun safety. This partnership will be a vehicle for Supergoop! to spotlight the brand’s mission to elevate skin cancer awareness alongside the many skincare and beauty benefits attributed to applying UV protection every single day.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7190451-supergoop-partnership-tennis-maria-sharapova-sun-protection-skincare
Eagle Rare Kentucky Straight Bourbon Whiskey has named Angie Goodwin of Calhoun, Ky., as the winner of the Grand Prize 2014 Rare Life Award. Eagle Rare will donate $40,000 to Goodwin’s charity, Thumbs Up for Lane Goodwin Childhood Cancer Foundation, and host an awards ceremony in Henderson on March 7. Angie and her late son Lane started the foundation to support childhood cancer research through funding and advocacy and to assist families battling childhood cancer by providing education, financial assistance and a volunteer network.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64624-eagle-rare-bourbon-angie-goodwin-grand-prize-2014-rare-life-award
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell’s existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65415-weill-cornell-medical-college-belfer-cancer-research-building-opening
